share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

諾瓦瓦克斯醫藥 | 4：持股變動聲明-高管 Dubovsky Filip
美股sec公告 ·  06/21 05:12
牛牛AI助理已提取核心訊息
On June 17, 2024, Novavax's President of R&D, Filip Dubovsky, completed a series of transactions involving the company's common stock. Dubovsky executed the sale of 13,904 shares at prices ranging from $14.46 to $14.54 per share, resulting in a total market value of $201,164.16. Prior to the sales, Dubovsky acquired the same number of shares through the exercise of derivative securities at prices between $6.09 and $6.97. Following these transactions, Dubovsky's direct holdings in Novavax common stock amounted to 66,613 shares.
On June 17, 2024, Novavax's President of R&D, Filip Dubovsky, completed a series of transactions involving the company's common stock. Dubovsky executed the sale of 13,904 shares at prices ranging from $14.46 to $14.54 per share, resulting in a total market value of $201,164.16. Prior to the sales, Dubovsky acquired the same number of shares through the exercise of derivative securities at prices between $6.09 and $6.97. Following these transactions, Dubovsky's direct holdings in Novavax common stock amounted to 66,613 shares.
2024年6月17日，諾瓦瓦克斯醫藥研發總裁Filip Dubovsky完成了一系列交易，涉及公司普通股。Dubovsky以每股14.46美元至14.54美元的價格出售了13,904股，導致總市值爲201,164.16美元。在出售前，Dubovsky通過衍生證券行權獲得相同數量的股份，價格介於6.09美元至6.97美元之間。在這些交易之後，Dubovsky在諾瓦瓦克斯醫藥的直接持股達到了66,613股。
2024年6月17日，諾瓦瓦克斯醫藥研發總裁Filip Dubovsky完成了一系列交易，涉及公司普通股。Dubovsky以每股14.46美元至14.54美元的價格出售了13,904股，導致總市值爲201,164.16美元。在出售前，Dubovsky通過衍生證券行權獲得相同數量的股份，價格介於6.09美元至6.97美元之間。在這些交易之後，Dubovsky在諾瓦瓦克斯醫藥的直接持股達到了66,613股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。